Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy

ObjectiveNeoadjuvant therapy is under investigation not only for unresectable clear cell renal cell carcinoma (ccRCC) (1) but also for locally invasive primary thyroid cancers (2). Herein, we describe two cases of locally invasive thyroid metastases from ccRCC treated surgically after neoadjuvant th...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana M. Hartl, Mohamed-Amine Bani, Abir Al Ghuzlan, Andreea-Elena Simonescu, Ingrid Breuskin, Alix Marhic, Laurence Albiges, Livia Lamartina, Julien Hadoux
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1543060/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850139545531580416
author Dana M. Hartl
Mohamed-Amine Bani
Abir Al Ghuzlan
Andreea-Elena Simonescu
Ingrid Breuskin
Alix Marhic
Laurence Albiges
Laurence Albiges
Livia Lamartina
Livia Lamartina
Julien Hadoux
Julien Hadoux
author_facet Dana M. Hartl
Mohamed-Amine Bani
Abir Al Ghuzlan
Andreea-Elena Simonescu
Ingrid Breuskin
Alix Marhic
Laurence Albiges
Laurence Albiges
Livia Lamartina
Livia Lamartina
Julien Hadoux
Julien Hadoux
author_sort Dana M. Hartl
collection DOAJ
description ObjectiveNeoadjuvant therapy is under investigation not only for unresectable clear cell renal cell carcinoma (ccRCC) (1) but also for locally invasive primary thyroid cancers (2). Herein, we describe two cases of locally invasive thyroid metastases from ccRCC treated surgically after neoadjuvant therapy to highlight the rationale and outcomes.Patients and methodsTwo patients, one woman and one man, both age 69, developed unresectable thyroid metastases from ccRCC, respectively, 20 and 13 years after nephrectomy for ccRCC. Patient 1 received lenvatinib and a bispecific anti–Programmed cell Death protein 1/ cytotoxic T-lymphocyte-associated protein 4 (PD-1/CTLA-4) antibody in the context of a clinical trial. The second patient received nivolumab and cabozantinib.ResultsThe observed tumor response in patient 1 showed a decrease in mean surgical complexity score from unresectable (prevertebral fascia invasion) to severe (risk of recurrent nerve paralysis) and in patient 2 from unresectable (prevertebral fascia) to moderate (superficial esophageal invasion). The recurrent nerve was invaded in patient 1, leading to a subtotal resection. Surgery was a total thyroidectomy extended to the internal jugular vein in patient 2. Hospitalization was 1 and 2 days, respectively. Postoperative dysphonia improved in patient 1 after 3 months. No complications occurred in the second patient, who received adjuvant radiation therapy. After surgery, systemic therapy was discontinued in both patients, and stable residual oligometastatic disease was followed.ConclusionNeoadjuvant therapy enabled a macroscopic resection of locally invasive thyroid metastases, preserving laryngeal function and allowing discontinuation of systemic therapy. This approach may be considered in these rare cases, although the impact on progression-free or overall survival is currently unknown.
format Article
id doaj-art-0bd6b3a3192a40baa126b4ca3a47e193
institution OA Journals
issn 2234-943X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-0bd6b3a3192a40baa126b4ca3a47e1932025-08-20T02:30:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15430601543060Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapyDana M. Hartl0Mohamed-Amine Bani1Abir Al Ghuzlan2Andreea-Elena Simonescu3Ingrid Breuskin4Alix Marhic5Laurence Albiges6Laurence Albiges7Livia Lamartina8Livia Lamartina9Julien Hadoux10Julien Hadoux11Division of Surgery and Anesthesiology, Head and Neck Oncology Service, Thyroid Surgery Unit, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FranceDepartment of Pathology, Gustave Roussy Cancer Campus, Villejuif, FranceDepartment of Pathology, Gustave Roussy Cancer Campus, Villejuif, FranceDepartment of Pathology, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of Surgery and Anesthesiology, Head and Neck Oncology Service, Thyroid Surgery Unit, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FranceDivision of Surgery and Anesthesiology, Head and Neck Oncology Service, Thyroid Surgery Unit, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FranceDepartment of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, FranceUniversity of Paris-Saclay, Le Kremlin-Bicêtre, FranceDepartment of Medical Imaging, Endocrine Oncology Service, Gustave Roussy Cancer Campus, Villejuif, FranceEndocan-Tuthyref Network, Villejuif, FranceDepartment of Medical Imaging, Endocrine Oncology Service, Gustave Roussy Cancer Campus, Villejuif, FranceEndocan-Tuthyref Network, Villejuif, FranceObjectiveNeoadjuvant therapy is under investigation not only for unresectable clear cell renal cell carcinoma (ccRCC) (1) but also for locally invasive primary thyroid cancers (2). Herein, we describe two cases of locally invasive thyroid metastases from ccRCC treated surgically after neoadjuvant therapy to highlight the rationale and outcomes.Patients and methodsTwo patients, one woman and one man, both age 69, developed unresectable thyroid metastases from ccRCC, respectively, 20 and 13 years after nephrectomy for ccRCC. Patient 1 received lenvatinib and a bispecific anti–Programmed cell Death protein 1/ cytotoxic T-lymphocyte-associated protein 4 (PD-1/CTLA-4) antibody in the context of a clinical trial. The second patient received nivolumab and cabozantinib.ResultsThe observed tumor response in patient 1 showed a decrease in mean surgical complexity score from unresectable (prevertebral fascia invasion) to severe (risk of recurrent nerve paralysis) and in patient 2 from unresectable (prevertebral fascia) to moderate (superficial esophageal invasion). The recurrent nerve was invaded in patient 1, leading to a subtotal resection. Surgery was a total thyroidectomy extended to the internal jugular vein in patient 2. Hospitalization was 1 and 2 days, respectively. Postoperative dysphonia improved in patient 1 after 3 months. No complications occurred in the second patient, who received adjuvant radiation therapy. After surgery, systemic therapy was discontinued in both patients, and stable residual oligometastatic disease was followed.ConclusionNeoadjuvant therapy enabled a macroscopic resection of locally invasive thyroid metastases, preserving laryngeal function and allowing discontinuation of systemic therapy. This approach may be considered in these rare cases, although the impact on progression-free or overall survival is currently unknown.https://www.frontiersin.org/articles/10.3389/fonc.2025.1543060/fullrenal cell carcinomathyroidmetastasisneoadjuvant therapykinase inhibitorsimmunotherapy
spellingShingle Dana M. Hartl
Mohamed-Amine Bani
Abir Al Ghuzlan
Andreea-Elena Simonescu
Ingrid Breuskin
Alix Marhic
Laurence Albiges
Laurence Albiges
Livia Lamartina
Livia Lamartina
Julien Hadoux
Julien Hadoux
Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
Frontiers in Oncology
renal cell carcinoma
thyroid
metastasis
neoadjuvant therapy
kinase inhibitors
immunotherapy
title Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
title_full Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
title_fullStr Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
title_full_unstemmed Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
title_short Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy
title_sort case report locally invasive thyroid metastases from renal cell carcinoma surgery after neoadjuvant therapy
topic renal cell carcinoma
thyroid
metastasis
neoadjuvant therapy
kinase inhibitors
immunotherapy
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1543060/full
work_keys_str_mv AT danamhartl casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT mohamedaminebani casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT abiralghuzlan casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT andreeaelenasimonescu casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT ingridbreuskin casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT alixmarhic casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT laurencealbiges casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT laurencealbiges casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT livialamartina casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT livialamartina casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT julienhadoux casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy
AT julienhadoux casereportlocallyinvasivethyroidmetastasesfromrenalcellcarcinomasurgeryafterneoadjuvanttherapy